Outcome of the Board Meeting held on 22.08.2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.5 pts less than Nifty Microcap 250 and 4.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The Board of Welcure Drugs & Pharmaceuticals approved two key capital actions on August 22, 2025. First, a stock split sub-dividing each equity share of face value Rs. 10 into 10 shares of Re. 1 each, aimed at improving liquidity and retail accessibility. Second, a bonus issue in the ratio of 1:10 (1 bonus share for every 10 held), entailing issuance of about 1.12 crore additional shares worth roughly Rs. 11.24 crore by capitalising securities premium or free reserves. The Board also approved increasing authorised share capital from Rs. 186 crore to Rs. 196 crore and amending the MOA to reflect these changes. Both the stock split and bonus are subject to shareholder approval via postal ballot, with record dates to be announced later. CSDL has been appointed as the e-voting agency. Free reserves stood at about Rs. 13.37 crore as of June 30, 2025. The actions are expected to be completed within approximately two months.
Both actions are generally viewed positively by retail investors — the stock split lowers the per-share price, making the stock more affordable and improving liquidity, while the bonus issue rewards existing shareholders with extra shares. Share price will adjust downward on the ex-date to reflect the split, but overall shareholder value remains unchanged.